Epidemiology and outcome of adult-onset Still's disease in the Northwestern Thrace region in Turkey

Clinical and Experimental Rheumatology

Volumn 33, Issue 6, 2015, Pages 818-823

  Balci, Mehmet Ali ^a   Pamuk, Omer Nuri ^a   Pamuk, Gulsum Emel ^a   Uzundere, Fatma Keskin ^b   Donmez, Salim ^a  

^a TRAKYA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b SIIRT STATE HOSPITAL   (Turkey)

Author keywords

Adult onset Still's disease; Epidemiology

Indexed keywords

ADULT; ADULT ONSET STILL DISEASE; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FEVER; FOLLOW UP; HUMAN; MALE; MEASUREMENT; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SEX RATIO; SORE THROAT; TURKEY (REPUBLIC); YOUNG ADULT; COMPLICATION; INCIDENCE; PHYSIOLOGIC MONITORING; STATISTICS AND NUMERICAL DATA; STILL'S DISEASE, ADULT-ONSET; TURKEY;

ANTIRHEUMATIC AGENT;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRALGIA; DEMOGRAPHY; FEMALE; FEVER; HUMANS; INCIDENCE; MALE; MONITORING, PHYSIOLOGIC; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; RETROSPECTIVE STUDIES; STILL'S DISEASE, ADULT-ONSET; TURKEY;

EID: 84957942877     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. STILL GF: On a form of chronic joint disease in children. Med Chir Trans 1897; 80: 47.
2. MELLINS ED, MACAUBAS C, GROM AA: Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011; 7: 416-26.
3. ROSSI-SEMERANO L, KONE-PAUT I: Is Still's disease an autoinflammatory syndrome? Int J Inflam 2012; 2012: 480373.
4. RIGANTE D, CANTARINI L: The systemiconset variant of juvenile idiopathic arthritis needs to be recorded as an automflammatory syndrome: comment on the review by Nigrovic. Arthritis Rheumatol 2014; 66: 2645.
5. KIM JJ, KIM JK, SHIM SC et al.: MEFV gene mutations and their clinical significance in Korean patients with adult-onset still's disease. Clin Exp Rheumatol 2013; 31 (Suppl. 77): 60-3.
6. WAKAI K, OHTA A, TAMAKOSHI A et al: Estimated prevalence and incidence of adult Still's disease: findings by a nationwide epidemiological survey in Japan. J Epidemiol 1997; 7: 221-5.
7. MAGADUR-JOLY G, BILLAUD E, BARRIER JH et al.: Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis 1995; 54: 587.
8. EVENSEN KJ, NOSSENT HC: Epidemiology and outcome of adult-onset Still's disease in Northern Norway. Scand J Rheumatol 2006; 35: 48-51.
9. WOUTERS JM, VAN DE PUTTE LB: Adult-onset Still's disease; clinical and laboratory features, treatment and progress of 45 cases. Q J Med 1986; 61: 1055-65.
10. POUCHOT J, ARLET J-B: Biological treatment in adult-onset Still's disease. Best Pract Res Clin Rheumatol 2012; 26: 477-87.
11. RIGANTE D, ANSUINI V, CALDARELLI M, BERTONI B, LA TORRACA I, STABiLE A: Hydrocephalus in CINCA syndrome treated with anakinra. Childs Nerv Syst 2006; 22: 334-7.
12. VITALE A, RIGANTE D, LUCHERINI OM et al: Biological treatments: new weapons in the management of monogenic automflammatory disorders. Mediators Inflamm 2013; 2013: 939847.
13. TER HAAR N, LACHMANN H, OZEN S et al: Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever/Eurotraps Projects. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013; 72: 678-85.
14. CANTARINI L, LUCHERINI OM, FREDIANI B et al.: Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromes. Int J Immunopathol Pharmacol 2011; 24: 827-36.
15. PAY S, TURKCAPAR N, KALYONCU M et al: Ankara Rheumatology Study Group. A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol 2006; 25: 639-44.
16. KALYONCU U, YAZISIZ V, EMMUNGIL H et al: "Delay of diagnosis in Still's disease is associated with a chronic/relapsing pattern: national, multicenter study of 356 patients. Ann Rheum Dis 2013; 72 (Suppl. 3): 330.
17. YAMAGUCHI M, OHTA A, TSUNEMATSU T et al: Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992; 19: 424-30.
18. ASANUMA YF, MIMURA T, TSUBOI H et al.: Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan. Mod Rheumatol 2014; 10: 1-8.
19. GERFAUD-VALENTIN M, MAUCORT-BOULCH D, HOT A et al: Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore) 2014; 93: 91-9.
20. COLINA M, ZUCCHINI W, CIANCIO G, ORZINCOLO C, TROTTA F, GOVONI M: The evolution of adult-onset Still disease: an observational and comparative study in a cohort of 76 Italian patients. Semin Arthritis Rheum 2011; 41: 279-85.
21. KIM YJ, KOO BS, KIM YG, LEE CK, YOO B: Clinical features and prognosis in 82 patients with adult-onset Still's disease. Clin Exp Rheumatol 2014; 32: 28-33.
22. LOPALCO G, CANTARINI L, VITALE A et al.: Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm 2015; 2015: 194864.
23. GIAMPIETRO C, RIDENE M, LEQUERRE T et al: CRI (Club Rhumatismes et Inflammation). Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken) 2013; 65: 822-6.
24. ILIOU C, PAPAGORAS C, TSIFETAKI N, VOULGARI PV, DROSOS AA: Adult-onset Still's disease: clinical, serological and therapeutic considerations. Clin Exp Rheumatol 2013; 31: 47-52.
25. SELMI C, CERIBELLI A, NAGUWA SM, CANTARINI L, SHOENFELD Y: Safety issues and concerns of new immunomodulators in rheumatology. Expert Opin Drug Saf 2015; 14: 389-99.
26. CANTARINI L, LOPALCO G, CASO F et al: Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behcet's disease. Autoimmun Rev 2015; 14: 1-9.
27. CAKIR E, ERDEM E, OZLU N, SEBER E, GENCER S, KILICASLAN Z: Demographic and microbial characteristics and drug resistance of childhood tuberculosis in Istanbul: analysis of 1,541 cases. J Infect Dev Ctries 2014; 8: 304-9.
28. ZUNIGA J, TORRES-GARCÍA D, SANTOS-MENDOZA T, RODRIGUEZ-REYNA TS, GRANADOS J, YUNIS EJ: Cellular and humoral mechanisms involved in the control of tuberculosis. Clin Dev Immunol 2012; 2012: 193923.
29. SUNDY JS, SCHUMACHER HR, KIVITZ A et al.: Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. J Rheumatol 2014; 41: 1703-11.